Dawwas GK, Barnes GD, Dietrich E, et al. - Direct oral anticoagulants (DOACs) are identified to have a potential promising role in patients with ACS and atrial fibrillation (AF) requiring combined antiplatelet therapy.

• From the United States-based commercial healthcare database, researchers included a total of 2,472 persons who initiated the combined therapy within 30 days following incident ACS diagnosis.

• These patients comprised 1,236 users of antiplatelet-DOAC and 1,236 users of antiplatelet-warfarin.

• Outcomes suggest correlation of using antiplatelet-DOAC following ACS diagnosis with a lower rate of recurrent CVD and major bleeding events when compared with using antiplatelet-warfarin.